Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer.
about
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCPost-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer
P2860
Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Proactive management strategie ...... ve non-small-cell lung cancer.
@en
Proactive management strategie ...... ve non-small-cell lung cancer.
@nl
type
label
Proactive management strategie ...... ve non-small-cell lung cancer.
@en
Proactive management strategie ...... ve non-small-cell lung cancer.
@nl
prefLabel
Proactive management strategie ...... ve non-small-cell lung cancer.
@en
Proactive management strategie ...... ve non-small-cell lung cancer.
@nl
P2860
P356
P1476
Proactive management strategie ...... ve non-small-cell lung cancer.
@en
P2093
Christina Baik
Eric S Schaefer
P2860
P356
10.2147/CMAR.S96471
P407
P577
2016-03-24T00:00:00Z